312:(COPD). These medications decrease immune system activity which in turn will decrease swelling of the airways, decrease airway resistance, and increase delivery of air to the alveoli during respiration. Unlike the SABAs, these medications do not provide relief of acute symptoms or asthmatic attacks, and their benefits are typically only seen after 3–4 weeks of therapy. Due to this delayed therapeutic response, it is essential that patients who are prescribed corticosteroids for respiratory disease are adherent to their medication regimen. In the ISOLDE trial, fluticasone therapy decreased the frequency of COPD exacerbations and the rate of health decline in patients with moderate-to-severe COPD; however, had little effect in decreasing the rate of FEV1 decline. Patients should be counseled to wash their mouth following use of inhaled corticosteroids to decrease the risk of developing
20:
294:
first-line therapy for quick relief in persistent and intermittent asthma and bronchospasm. Patients may experience dizziness, heart palpitations, hyperglycemia, diarrhea and muscle cramps when taking these medications. Importantly, medications that antagonize the β2 receptor (β-blockers) may significantly increase the risk of asthma exacerbations, and are generally avoided in asthmatic patients.
124:
In a patient with EIB, exercise initially follows the normal patterns of bronchodilation. However, by three minutes, the constriction sets in, which peaks at around 10–15 minutes, and usually resolves itself by an hour. During an episode of this type of bronchoconstriction, the levels of inflammatory
191:
in sensitized subjects develops into bronchoconstriction within 10 minutes, reaches a maximum within 30 minutes, and usually resolves itself within one to three hours. In some subjects, the constriction does not return to normal, and recurs after three to four hours, which may last up to a day or
172:
This specific condition, in the general population, can vary between 7 and 20 percent. This increases to around 80 percent in those with symptomatic asthma. In many cases, however, the constriction, even during or after strenuous exercise, is not clinically significant except in cases of severe to
82:
With emphysema the shortness of breath due to effective bronchoconstriction from excessive very thick mucus blockage (it is so thick that great difficulty is encountered in expelling it resulting in near exhaustion at times) can bring on panic attacks unless the individual expects this and has
293:
which lasts 12 hours. For example, during an acute asthma exacerbation where airway smooth muscle is constricted, inhalation of SABAs provide rapid relief of symptoms—within 5–15 minutes—and are typically called "rescue inhalers". Due to their fast onset of action, they have been selected as
331:. Onset of action for SAMAs is typically between 30 and 60 minutes, making these drugs less efficacious in treating acute asthma attacks and bronchospasm. Most common side effects for these drugs may include dry mouth, headache, urinary tract infection, and bronchitis.
284:
Medications that stimulate the β2 receptor subtype on pulmonary smooth muscle will result in smooth muscle relaxation, bronchodilation, and increased airflow into the lungs during inhalation. These medications include short-acting beta agonists (SABAs) such as
261:
pathway, that will end in an increase of intracellular calcium concentrations and therefore contraction of the smooth muscle cell. The muscle contraction will cause the diameter of the bronchus to decrease, therefore increasing its resistance to airflow.
164:
The underlying cause of this type of bronchoconstriction appear to be the large volume of cool, dry air inhaled during strenuous exercise. The condition appears to improve when the air inhaled is more fully humidified and closer to
322:
Blocking the muscarinic acetylcholine receptors in pulmonary smooth muscle tissue results in a decrease in smooth muscle tone and bronchodilation. These medications include short-acting muscarinic antagonists (SAMAs) such as
635:"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial"
91:
is mandatory if this incurable disease is to be treated. Prevention of bronchoconstriction by this pathway is vital for people with emphysema and there are several
215:
Bronchoconstriction is defined as the narrowing of the airways in the lungs (bronchi and bronchioles). Air flow in air passages can get restricted in three ways:
157:, of generally less than four hours, during which if exercise is repeated, the bronchoconstriction is less emphasised. This is probably caused by the release of
308:) are typically used when bronchoconstrictive disease has advanced to a persistent inflammatory state, more specifically in persistent or severe asthma and
725:
87:
to more quickly transfer oxygen to the blood via the damaged alveoli resulting from the disease. The most common cause of emphysema is smoking and
801:
442:
Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, Storms WW, Weiler JM, Cheek FM, Wilson KC, Anderson SD (1 May 2013).
682:
Panning CA, DeBisschop M (Feb 2003). "Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease".
184:
While a different cause, this has very similar symptoms, namely the immunological reaction involving release of inflammatory mediators.
1167:
385:
277:
depends on the severity and etiology of the underlying disease and can be treated with combinations of the following medications:
770:
309:
794:
246:
1281:
762:
1238:
1093:
153:. After exercise, the conditions will fade within one to three minutes. In most people with EIB, this is followed by a
522:
598:
Foresi A, et al. (1993). "Bronchial responsiveness to inhaled propranolol in asthmatic children and adults".
1276:
787:
349:
are indicated for specific diseases and may only provide bronchoconstriction relief to these studied populations.
1157:
230:
265:
Bronchoconstriction is common in people with respiratory problems, such as asthma, COPD, and cystic fibrosis.
884:
121:. It is also preferred due to the former term giving the false impression that asthma is caused by exercise.
1006:
733:
489:
538:
Rau JL (Jul 2000). "Inhaled adrenergic bronchodilators: historical development and clinical application".
1176:
1125:
976:
444:"An Official American Thoracic Society Clinical Practice Guideline: Exercise-induced Bronchoconstriction"
1130:
1038:
969:
950:
253:
on their membrane. The activation of these receptors by acetylcholine will activate an intracellular
1114:
981:
945:
839:
567:"Expert Panel 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007"
1147:
1016:
109:
443:
964:
911:
901:
810:
512:
1152:
1088:
19:
1207:
1062:
1026:
861:
856:
421:
84:
274:
176:
In May 2013, the
American Thoracic Society issued the first treatment guidelines for EIB.
8:
324:
47:
1217:
1212:
1192:
1050:
926:
707:
413:
328:
767:
1255:
1171:
1137:
939:
894:
876:
758:
Pharmacotherapy of bronchoconstriction in patients with asthma by antiepileptic drugs
699:
664:
659:
634:
615:
547:
518:
463:
405:
359:
88:
711:
633:
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (May 13, 2000).
1072:
1021:
931:
846:
691:
654:
646:
607:
578:
455:
417:
397:
166:
1250:
1098:
1067:
774:
611:
258:
118:
92:
695:
564:
1196:
1186:
1043:
1001:
866:
583:
566:
459:
234:
158:
650:
289:
which typically last 4–6 hours, and long-acting beta agonists (LABAs) such as
1270:
1202:
958:
871:
401:
242:
238:
35:
1142:
1011:
993:
851:
703:
668:
551:
467:
409:
364:
338:
126:
619:
1181:
779:
386:"Salt Intake, Asthma, and Exercise-Induced Bronchoconstriction: A Review"
346:
313:
301:
204:
134:
96:
1243:
1162:
1057:
834:
829:
768:
Salt Intake, Asthma, and
Exercise-Induced Bronchoconstriction: A Review
305:
290:
138:
1119:
286:
254:
130:
71:
59:
441:
377:
95:
medications that in combination with mucous thinning agents such as
342:
222:
an inflammation in the middle layers of the bronchi and bronchioles
188:
74:
can bring on the symptoms in an otherwise asymptomatic individual.
67:
43:
39:
219:
a spasmodic state of the smooth muscles in bronchi and bronchioles
514:
Lung function physiology, measurement and application in medicine
824:
146:
142:
63:
245:
layer surrounding the bronchi. These smooth muscle cells have
337:
Other prescription and over-the-counter medications, such as
31:
58:
The condition has a number of causes, the most common being
1221:
920:
517:(6th ed.). Malden, Mass.: Blackwell Pub. p. 165.
632:
448:
American
Journal of Respiratory and Critical Care Medicine
565:
National Asthma
Education and Prevention Program (2007).
150:
327:, and long-acting muscarinic antagonists (LAMA) such as
757:
273:
Medical management of transient bronchoconstriction or
179:
102:
23:
Illustration depicting bronchoconstriction (Asthma)
149:expressing CD 23, causing increased production of
681:
16:Constriction of the terminal airways in the lungs
1268:
510:
229:The bronchial spasm is due to the activation of
795:
383:
203:Bronchoconstriction can occur as a result of
763:Why Do So Many Winter Olympians Have Asthma?
316:, a common side effect of these medications.
99:cause significant improvement in breathing.
320:Muscarinic antagonists (anti-cholinergics):
809:
802:
788:
30:is the constriction of the airways in the
658:
582:
207:, even when the allergen is not inhaled.
18:
487:
113:, the preferred and more accurate term
1269:
597:
783:
310:chronic obstructive pulmonary disease
34:due to the tightening of surrounding
1168:oxygen–hemoglobin dissociation curve
237:parasympathetic fibers will release
180:Allergen-induced bronchoconstriction
115:exercise-induced bronchoconstriction
103:Exercise-induced bronchoconstriction
537:
511:Cotes J, Chinn D, Miller M (2006).
141:are activated, with an increase in
13:
1094:hypoxic pulmonary vasoconstriction
14:
1293:
751:
257:, that in turn will activate the
492:. Merck Manuals Consumer Version
390:The Physician and Sportsmedicine
241:causing the constriction of the
718:
384:Mickleborough TD (April 2010).
675:
626:
591:
558:
531:
504:
481:
435:
300:Inhaled corticosteroids (e.g.
231:parasympathetic nervous system
225:excessive production of mucus.
1:
370:
268:
210:
192:more. The first is named the
145:expressing CD25 (IL-2R), and
612:10.1183/09031936.93.06020181
77:
7:
1126:Ventilation/perfusion ratio
977:pulmonary stretch receptors
696:10.1592/phco.23.2.183.32082
353:
117:better reflects underlying
10:
1298:
1282:Pulmonary function testing
1158:alveolar–arterial gradient
584:10.1016/j.jaci.2007.09.029
460:10.1164/rccm.201303-0437st
1231:
1107:
1081:
1039:respiratory minute volume
992:
951:ventral respiratory group
910:
817:
651:10.1136/bmj.320.7245.1297
53:
946:dorsal respiratory group
840:obligate nasal breathing
402:10.3810/psm.2010.04.1769
194:early asthmatic response
125:mediators, particularly
1148:pulmonary gas pressures
198:late asthmatic response
110:exercise-induced asthma
1277:Respiratory physiology
902:mechanical ventilation
811:Respiratory physiology
571:J Allergy Clin Immunol
107:More generally termed
24:
1153:alveolar gas equation
1089:pulmonary circulation
488:Miles MC, Peters SP.
196:, and the latter the
137:, increase. TH2-type
22:
1208:respiratory quotient
1063:body plethysmography
982:Hering–Breuer reflex
857:pulmonary surfactant
726:"Treatment for COPD"
282:B-receptor agonists:
173:moderate emphysema.
85:pursed lip breathing
83:effectively learned
1051:Lung function tests
885:hyperresponsiveness
48:shortness of breath
28:Bronchoconstriction
1218:diffusion capacity
1213:arterial blood gas
1193:carbonic anhydrase
927:pneumotaxic center
773:2010-12-19 at the
645:(7245): 1297–303.
275:chronic bronchitis
38:, with consequent
25:
1264:
1263:
1172:Oxygen saturation
1138:zones of the lung
877:airway resistance
360:Bronchodilatation
155:refractory period
89:smoking cessation
1289:
1073:nitrogen washout
932:apneustic center
847:respiratory rate
804:
797:
790:
781:
780:
745:
744:
742:
741:
732:. Archived from
722:
716:
715:
679:
673:
672:
662:
630:
624:
623:
595:
589:
588:
586:
562:
556:
555:
535:
529:
528:
508:
502:
501:
499:
497:
485:
479:
478:
476:
474:
454:(9): 1016–1027.
439:
433:
432:
430:
429:
420:. Archived from
381:
298:Corticosteroids:
167:body temperature
1297:
1296:
1292:
1291:
1290:
1288:
1287:
1286:
1267:
1266:
1265:
1260:
1251:oxygen toxicity
1227:
1115:ventilation (V)
1103:
1099:pulmonary shunt
1077:
1068:peak flow meter
988:
906:
813:
808:
775:Wayback Machine
754:
749:
748:
739:
737:
724:
723:
719:
684:Pharmacotherapy
680:
676:
631:
627:
596:
592:
563:
559:
536:
532:
525:
509:
505:
495:
493:
486:
482:
472:
470:
440:
436:
427:
425:
382:
378:
373:
356:
271:
259:phospholipase C
250:
213:
182:
119:pathophysiology
105:
93:anticholinergic
80:
56:
17:
12:
11:
5:
1295:
1285:
1284:
1279:
1262:
1261:
1259:
1258:
1253:
1248:
1247:
1246:
1235:
1233:
1229:
1228:
1226:
1225:
1215:
1210:
1205:
1200:
1197:chloride shift
1190:
1187:Haldane effect
1184:
1179:
1174:
1165:
1160:
1155:
1150:
1145:
1140:
1135:
1134:
1133:
1128:
1117:
1111:
1109:
1105:
1104:
1102:
1101:
1096:
1091:
1085:
1083:
1079:
1078:
1076:
1075:
1070:
1065:
1060:
1055:
1053:
1047:
1046:
1044:FEV1/FVC ratio
1041:
1036:
1034:
1030:
1029:
1024:
1019:
1014:
1009:
1004:
998:
996:
990:
989:
987:
986:
985:
984:
974:
973:
972:
967:
959:chemoreceptors
955:
954:
953:
948:
936:
935:
934:
929:
916:
914:
908:
907:
905:
904:
899:
898:
897:
892:
887:
879:
874:
869:
867:elastic recoil
864:
859:
854:
849:
844:
843:
842:
837:
832:
821:
819:
815:
814:
807:
806:
799:
792:
784:
778:
777:
765:
760:
753:
752:External links
750:
747:
746:
717:
674:
625:
590:
557:
530:
523:
503:
480:
434:
396:(1): 118–131.
375:
374:
372:
369:
368:
367:
362:
355:
352:
351:
350:
332:
317:
295:
270:
267:
248:
235:Postganglionic
227:
226:
223:
220:
212:
209:
187:Inhalation of
181:
178:
159:prostaglandins
104:
101:
79:
76:
55:
52:
15:
9:
6:
4:
3:
2:
1294:
1283:
1280:
1278:
1275:
1274:
1272:
1257:
1254:
1252:
1249:
1245:
1242:
1241:
1240:
1239:high altitude
1237:
1236:
1234:
1232:Insufficiency
1230:
1223:
1219:
1216:
1214:
1211:
1209:
1206:
1204:
1203:oxyhemoglobin
1201:
1198:
1194:
1191:
1188:
1185:
1183:
1180:
1178:
1175:
1173:
1169:
1166:
1164:
1161:
1159:
1156:
1154:
1151:
1149:
1146:
1144:
1141:
1139:
1136:
1132:
1129:
1127:
1124:
1123:
1121:
1118:
1116:
1113:
1112:
1110:
1106:
1100:
1097:
1095:
1092:
1090:
1087:
1086:
1084:
1080:
1074:
1071:
1069:
1066:
1064:
1061:
1059:
1056:
1054:
1052:
1049:
1048:
1045:
1042:
1040:
1037:
1035:
1032:
1031:
1028:
1025:
1023:
1020:
1018:
1015:
1013:
1010:
1008:
1005:
1003:
1000:
999:
997:
995:
991:
983:
980:
979:
978:
975:
971:
968:
966:
963:
962:
961:
960:
956:
952:
949:
947:
944:
943:
942:
941:
937:
933:
930:
928:
925:
924:
923:
922:
918:
917:
915:
913:
909:
903:
900:
896:
893:
891:
888:
886:
883:
882:
880:
878:
875:
873:
872:hysteresivity
870:
868:
865:
863:
860:
858:
855:
853:
850:
848:
845:
841:
838:
836:
833:
831:
828:
827:
826:
823:
822:
820:
816:
812:
805:
800:
798:
793:
791:
786:
785:
782:
776:
772:
769:
766:
764:
761:
759:
756:
755:
736:on 2014-10-08
735:
731:
727:
721:
713:
709:
705:
701:
697:
693:
689:
685:
678:
670:
666:
661:
656:
652:
648:
644:
640:
636:
629:
621:
617:
613:
609:
605:
601:
594:
585:
580:
576:
572:
568:
561:
553:
549:
546:(7): 854–63.
545:
541:
534:
526:
524:9781444312836
520:
516:
515:
507:
491:
484:
469:
465:
461:
457:
453:
449:
445:
438:
424:on 2010-12-19
423:
419:
415:
411:
407:
403:
399:
395:
391:
387:
380:
376:
366:
363:
361:
358:
357:
348:
344:
340:
336:
333:
330:
326:
321:
318:
315:
311:
307:
303:
299:
296:
292:
288:
283:
280:
279:
278:
276:
266:
263:
260:
256:
252:
244:
243:smooth muscle
240:
239:acetylcholine
236:
232:
224:
221:
218:
217:
216:
208:
206:
201:
199:
195:
190:
185:
177:
174:
170:
168:
162:
160:
156:
152:
148:
144:
140:
136:
132:
128:
122:
120:
116:
112:
111:
100:
98:
94:
90:
86:
75:
73:
69:
65:
61:
51:
49:
45:
41:
37:
36:smooth muscle
33:
29:
21:
1143:gas exchange
1108:Interactions
1033:calculations
994:Lung volumes
957:
938:
919:
890:constriction
889:
852:respirometer
738:. Retrieved
734:the original
729:
720:
690:(2): 183–9.
687:
683:
677:
642:
638:
628:
606:(2): 181–8.
603:
600:Eur Respir J
599:
593:
577:: S94–S138.
574:
570:
560:
543:
539:
533:
513:
506:
494:. Retrieved
483:
471:. Retrieved
451:
447:
437:
426:. Retrieved
422:the original
393:
389:
379:
365:Bronchospasm
339:theophylline
334:
319:
297:
281:
272:
264:
247:muscarinic M
228:
214:
202:
197:
193:
186:
183:
175:
171:
163:
154:
127:leukotrienes
123:
114:
108:
106:
81:
57:
27:
26:
1182:Bohr effect
1082:Circulation
818:Respiration
540:Respir Care
347:montelukast
325:ipratropium
314:oral thrush
302:fluticasone
205:anaphylaxis
139:lymphocytes
135:interleukin
97:Guaifenesin
62:as well as
1271:Categories
1244:death zone
1163:hemoglobin
1058:spirometry
1017:dead space
970:peripheral
895:dilatation
881:bronchial
862:compliance
835:exhalation
830:inhalation
740:2014-11-03
496:5 November
428:2010-07-07
371:References
329:tiotropium
306:budesonide
291:salmeterol
269:Management
211:Physiology
1120:Perfusion
287:albuterol
255:G protein
251:receptors
189:allergens
131:histamine
78:Emphysema
72:allergies
60:emphysema
1131:V/Q scan
771:Archived
712:35205801
704:12587807
669:10807619
552:10926383
490:"Asthma"
473:19 April
468:23634861
410:20424409
354:See also
343:cromolyn
68:Exercise
44:wheezing
40:coughing
1256:hypoxia
1177:2,3-BPG
965:central
940:medulla
912:Control
620:8444289
418:5761664
345:, and
147:B cells
143:T cells
825:breath
710:
702:
667:
657:
618:
550:
521:
466:
416:
408:
335:Other:
133:, and
64:asthma
54:Causes
46:, and
708:S2CID
660:27372
414:S2CID
32:lungs
1222:DLCO
1122:(Q)
921:pons
700:PMID
665:PMID
616:PMID
548:PMID
519:ISBN
498:2016
475:2018
464:PMID
406:PMID
70:and
1027:PEF
1007:FRC
730:NIH
692:doi
655:PMC
647:doi
643:320
639:BMJ
608:doi
579:doi
575:120
456:doi
452:187
398:doi
151:IgE
1273::
1022:CC
1012:Vt
1002:VC
728:.
706:.
698:.
688:23
686:.
663:.
653:.
641:.
637:.
614:.
602:.
573:.
569:.
544:45
542:.
462:.
450:.
446:.
412:.
404:.
394:38
392:.
388:.
341:,
304:,
233:.
200:.
169:.
161:.
129:,
66:.
50:.
42:,
1224:)
1220:(
1199:)
1195:(
1189:)
1170:(
803:e
796:t
789:v
743:.
714:.
694::
671:.
649::
622:.
610::
604:6
587:.
581::
554:.
527:.
500:.
477:.
458::
431:.
400::
249:3
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
